Wells Fargo analyst Tiago Fauth raised the firm’s price target on Insmed (INSM) to $130 from $119 and keeps an Overweight rating on the shares. While literature directly linking NSP inhibition to clinical endpoints in CRSsNP is lacking, the firm sees merit in the approach and views the risk/reward as attractive, given low investor expectations and a meaningful market opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Promising Outlook: Buy Rating Backed by Brenso Launch and Market Potential
- Insmed price target raised to $108 from $102 at Morgan Stanley
- Insmed price target raised to $111 from $90 at JPMorgan
- Insmed, Deutsche Bank, Booking, Uber, DoorDash: Trending by Analysts
- Insmed Announces $650 Million Public Stock Offering